-
整合素αvβ3在新生血管内皮细胞和恶性肿瘤细胞表面高表达,而在正常组织中不表达或低表达。精氨酸-甘氨酸-天冬氨酸(arginine-glycine-aspatic acid,RGD)三肽序列是一种小分子肽,其与整合素αvβ3受体存在配体受体关系,且有较高的选择性和亲和力[1]。Parihar等[2]的研究结果显示,68Ga标记的RGD PET/CT显像对放射性碘难治性分化型甲状腺癌(radioiodine refractory DTC,RAIR-DTC)病灶的检出率为82.3%。在国内,99Tcm简单易得,性价比高,且SPECT/CT较PET/CT更普及,因此99Tcm标记的RGD SPECT/CT显像有望在国内推广。Zhao等[3]初步报道了整合素受体99Tcm-甲苯磺酸钠烟酰胺腙聚乙二醇双环RGD肽(简称99Tcm-3PRGD2)SPECT/CT显像用于RAIR-DTC病灶的定位和生长评估的可行性。但目前国内关于99Tcm-3PRGD2 SPECT/CT显像在RAIR-DTC中应用的文献较少。本研究旨在评价99Tcm-3PRGD2 SPECT/CT显像对RAIR-DTC病灶的诊断效能,为抗血管生成酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKI)在RAIR-DTC中的应用提供分子影像可视化依据。
-
在59例患者中共检测出295个病灶,其中能通过本研究验证标准定性且可进行SUVmax定量的病灶共276个。这276个病灶中有活体组织病理学检查结果的病灶共36个,无活体组织病理学检查结果的病灶共240个,所有病灶均结合相应的临床随访结果加以验证。
-
99Tcm-3PRGD2 SPECT/CT显像对276个RAIR-DTC病灶诊断的灵敏度、特异度、准确率、阳性预测值、阴性预测值分别为94.9%(203/214,95%CI:90.7%~97.3%)、88.7%(55/62,95%CI:77.5%~95.0%)、93.5%(258/276,95%CI:88.5%~95.3%)、96.7% (203/210,95%CI:93.0%~98.5%)、83.3% (55/66,95%CI:71.7%~91.0%)。ROC曲线分析结果显示,界定是否为RAIR-DTC病灶的SUVmax的最佳临界值为2.70,AUC为0.874,灵敏度为88.6%,特异度为81.8%,约登指数为0.704。
-
Pearson相关分析结果显示,TL与病灶SUVmax呈正相关(r=0.635,P=0.001);sTg水平与SUVmax呈正相关(r=0.811,P=0.001)(图1A、1B)。
-
对接受TKI治疗的22例患者的59个病灶进行研究的结果显示,SUVmax、TL及sTg水平在TKI治疗前后的差异均有统计学意义(t=11.027、6.205、3.928,均P=0.001,表1)。TKI治疗前后99Tcm-3PRGD2 SPECT/CT显像变化的典型病例见图2。
时间 SUVmax TL(cm) sTg水平(ng/ml) 治疗前 5.56±2.00 1.97±1.22 3369.45±3443.24 治疗后 3.68±1.43 1.12±0.57 899.62±671.15 t值 11.027 6.205 3.928 P值 0.001 0.001 0.001 注:RAIR-DTC为放射性碘难治性分化型甲状腺癌;3PRGD2为甲苯磺酸钠烟酰胺腙聚乙二醇双环精氨酸-甘氨酸-天冬氨酸肽;SPECT为单光子发射计算机体层摄影术;CT为计算机体层摄影术;SUVmax为最大标准化摄取值;TL为病灶长径;sTg为刺激性甲状腺球蛋白 表 1 RAIR-DTC患者酪氨酸激酶抑制剂治疗前后99Tcm- 3PRGD2 SPECT/CT显像病灶相关参数的变化(
)$\bar x\pm s $ Table 1. Changes of parameters related to 99Tcm-SPECT/CT imaging in patients with radioiodine refractory differentiated thyroid cancer before and after tyrosine kinase inhibitors treatment (
)$\bar x\pm s $ -
18F-FDG PET/CT显像和99Tcm-3PRGD2 SPECT/CT显像检测RAIR-DTC阳性病灶的灵敏度分别为96.7%(59/61)和93.4%(57/61),特异度分别为84.6%(11/13)和92.3%(12/13)。ROC曲线分析结果显示,18F-FDG PET/CT显像的AUC为86.8%(95%CI:76.1%~97.6%),99Tcm-3PRGD2 SPECT/CT显像的AUC为89.0%(95%CI:80.4%~97.5%),2种方法的AUC差异无统计学意义(Z=0.312,P=0.753,图3)。Spearman相关分析结果显示,99Tcm-3PRGD2 SPECT/CT显像与18F-FDG PET/CT显像检出阳性病灶的SUVmax呈正相关,且差异有统计学意义(r=0.560,P=0.001,图4)。
99Tcm-3PRGD2 SPECT/CT显像在不摄碘进展性放射性碘难治性分化型甲状腺癌中的诊断价值
99Tcm-3PRGD2 SPECT/CT imaging in the diagnosis of progressive radioiodine refractory differentiated thyroid cancer without iodine uptake
-
摘要:
目的 评价99Tcm-甲苯磺酸钠烟酰胺腙聚乙二醇双环精氨酸-甘氨酸-天冬氨酸肽(简称99Tcm-3PRGD2) SPECT/CT显像对不摄碘进展性放射性碘难治性分化型甲状腺癌(RAIR-DTC)的诊断效能。 方法 前瞻性选择2019年10月至2022年5月在福建省立医院行99Tcm-3PRGD2 SPECT/CT检查的59例RAIR-DTC患者,其中男性17例、女性42例,中位年龄为51(28,80)岁。所有患者均行99Tcm-3PRGD2 SPECT/CT显像,其中22例接受酪氨酸激酶抑制剂(TKI)治疗,37例接受促甲状腺激素(TSH)抑制治疗(13例在2周内接受了18F-FDG PET/CT显像)。取每例患者最大病灶的最大标准化摄取值(SUVmax)进行分析。采用ROC曲线评估99Tcm-3PRGD2 SPECT/CT显像的诊断效能并计算99Tcm-3PRGD2 SPECT/CT显像检出RAIR-DTC病灶的SUVmax临界值;采用Pearson相关分析法分析病灶长径(TL)、刺激性甲状腺球蛋白(sTg)水平与SUVmax的相关性;采用配对t检验比较分析RAIR-DTC患者TKI治疗前后sTg水平、SUVmax、TL间的关系;采用Spearman分析法分析99Tcm-3PRGD2 SPECT/CT显像与18F-FDG PET/CT显像在检出阳性病灶的SUVmax之间的关系。 结果 59例RAIR-DTC患者的276个病灶被纳入分析,其中TKI治疗前后对比病灶59个。99Tcm-3PRGD2 SPECT/CT显像对RAIR-DTC病灶诊断的灵敏度和特异度分别为94.9% (95%CI:90.7%~97.3%)和88.7%(95%CI:77.5%~95.0%)。ROC曲线结果显示,99Tcm-3PRGD2 SPECT/CT显像检出RAIR-DTC病灶的SUVmax临界值为2.70。Pearson相关分析结果显示,靶病灶的SUVmax与sTg水平、TL均呈正相关(r=0.811、0.635,均P=0.001)。22例患者经TKI治疗后,RAIR-DTC病灶的SUVmax显著降低(t=11.027,P=0.001)。Spearman相关分析结果显示,99Tcm-3PRGD2 SPECT/CT显像与18F-FDG PET/CT显像在检出阳性病灶的SUVmax间呈正相关(r=0.560,P=0.001),且ROC曲线分析结果显示,99Tcm-3PRGD2 SPECT/CT显像对RAIR-DTC病灶的诊断效能与18F-FDG PET/CT显像的差异无统计学意义(Z=0.312,P=0.753)。 结论 99Tcm-3PRGD2 SPECT/CT显像对不摄碘进展性RAIR-DTC的诊断具有较高的灵敏度和特异度,与18F-FDG PET/CT显像相似。 -
关键词:
- 甲状腺肿瘤 /
- 碘放射性同位素 /
- 整合素αvβ3受体 /
- 单光子发射计算机体层摄影术 /
- 正电子发射断层显像术 /
- 体层摄影术,X线计算机
Abstract:Objective To evaluate the diagnostic efficiency of 99Tcm-sodium toluene sulfonate nicotinamide hydrazone PEGylated bicyclic arginine-glycine-aspatic acid peptide (abbreviation 99Tcm-3PRGD2) SPECT/CT imaging to progressive radioiodine refractory differentiated thyroid cancer (RAIR-DTC) without iodine uptake. Methods A total of 59 patients with RAIR-DTC who underwent 99Tcm-3PRGD2 SPECT/CT examination in Fujian Provincial Hospital from October 2019 to May 2022 were prospectively selected, including 17 males and 42 females, with a median age of 51 (28, 80) years. All patients underwent 99Tcm-3PRGD2 SPECT/CT, among them, 22 patients were treated with a tyrosine kinase inhibitor (TKI), and 37 patients had thyroid-stimulating hormone (TSH) inhibition [13 patients underwent 18F-fluorodeoxyglucose (FDG) PET/CT within two weeks]. Maximum standardized uptake value (SUVmax) of the lesion with the largest-length diameter in each patient was analyzed. The diagnostic efficiency of 99Tcm-3PRGD2 SPECT/CT imaging was evaluated by receiver operating characteristic (ROC) curves analysis and was also used to calculate the SUVmax cut-off value of 99Tcm-3PRGD2 SPECT/CT to assist in the detection of RAIR-DTC lesions. Using Pearson correlation analysis method to analyze the correlations between the target lesion (TL), stimulated thyroglobulin (sTg) levels and SUVmax. The relationships between the sTg levels, SUVmax and TL in RAIR-DTC patients before and after TKI treatment were analyzed by paired t test. Results A total of 276 lesions from 59 RAIR-DTC patients were included in the analysis. These 59 lesions were compared before and after TKI treatment. The sensitivity and specificity of 99Tcm-3PRGD2 SPECT/CT imaging for the diagnosis of RAIR-DTC lesions were 94.9% (95%CI: 90.7%–97.3%) and 88.7% (95%CI: 77.5%–95.0%), respectively. The ROC curves results showed that the cut-off value of SUVmax for RAIR-DTC lesions detected by 99Tcm-3PRGD2 SPECT/CT imaging was 2.70. The results of the Pearson correlation analysis showed that the SUVmax of the target lesions was positively correlated with the sTg levels and TL (r=0.811, 0.635, both P=0.001). The paired t test results showed that SUVmax in RAIR-DTC lesions was significantly decreased before and after TKI treatment (t=11.027, P=0.001). Spearman correlation analysis showed that there was a positive correlation between 99Tcm-3PRGD2 SPECT/CT imaging and 18F-FDG PET/CT imaging in detecting SUVmax of positive lesions (r=0.560, P=0.001). However, the results of ROC curves analysis did not show statistical significance in the diagnostic efficiency of 99Tcm-3PRGD2 SPECT/CT imaging for RAIR-DTC lesions versus 18F-FDG PET/CT imaging (Z=0.312, P=0.753). Conclusion 99Tcm-3PRGD2 SPECT/CT imaging had high sensitivity and specificity in the diagnosis of progressive RAIR-DTC without iodine uptake, similar to 18F-FDG PET/CT. -
表 1 RAIR-DTC患者酪氨酸激酶抑制剂治疗前后99Tcm- 3PRGD2 SPECT/CT显像病灶相关参数的变化(
)$\bar x\pm s $ Table 1. Changes of parameters related to 99Tcm-SPECT/CT imaging in patients with radioiodine refractory differentiated thyroid cancer before and after tyrosine kinase inhibitors treatment (
)$\bar x\pm s $ 时间 SUVmax TL(cm) sTg水平(ng/ml) 治疗前 5.56±2.00 1.97±1.22 3369.45±3443.24 治疗后 3.68±1.43 1.12±0.57 899.62±671.15 t值 11.027 6.205 3.928 P值 0.001 0.001 0.001 注:RAIR-DTC为放射性碘难治性分化型甲状腺癌;3PRGD2为甲苯磺酸钠烟酰胺腙聚乙二醇双环精氨酸-甘氨酸-天冬氨酸肽;SPECT为单光子发射计算机体层摄影术;CT为计算机体层摄影术;SUVmax为最大标准化摄取值;TL为病灶长径;sTg为刺激性甲状腺球蛋白 -
[1] Wang LJ, Shi JY, Kim YS, et al. Improving tumor-targeting capability and pharmacokinetics of 99mTc-labeled cyclic RGD dimers with PEG4 linkers[J]. Mol Pharm, 2009, 6(1): 231−245. DOI: 10.1021/mp800150r. [2] Parihar AS, Mittal BR, Kumar R, et al. 68Ga-DOTA-RGD2 positron emission tomography/computed tomography in radioiodine refractory thyroid cancer: prospective comparison of diagnostic accuracy with 18F-FDG positron emission tomography/computed tomography and evaluation toward potential theranostics[J]. Thyroid, 2020, 30(4): 557−567. DOI: 10.1089/thy.2019.0450. [3] Zhao D, Jin XN, Li F, et al. Integrin αvβ3 imaging of radioactive iodine-refractory thyroid cancer using 99mTc-3PRGD2[J]. J Nucl Med, 2012, 53(12): 1872−1877. DOI: 10.2967/jnumed.112.107821. [4] 中华医学会核医学分会. 131I治疗分化型甲状腺癌指南(2021版)[J]. 中华核医学与分子影像杂志, 2021, 41(4): 218−241. DOI: 10.3760/cma.j.cn321828-20201113-00412.
Chinese Medical Association. Guidelines for radioiodine therapy of differentiated thyroid cancer (2021 edition)[J]. Chin J Nucl Med Mol Imaging, 2021, 41(4): 218−241. DOI: 10.3760/cma.j.cn321828-20201113-00412.[5] 中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)分化型甲状腺癌诊疗指南2021[J]. 肿瘤预防与治疗, 2021, 34(12): 1164−1201. DOI: 10.3969/j.issn.1674-0904.2021.12.013.
Guidelines Working Committee of Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology (CSCO) differentiated thyroid cancer[J]. J Cancer Control Treat, 2021, 34(12): 1164−1201. DOI: 10.3969/j.issn.1674-0904.2021.12.013.[6] Jia B, Liu ZF, Zhu ZH, et al. Blood clearance kinetics, biodistribution, and radiation dosimetry of a kit-formulated integrin αvβ3-selective radiotracer 99mTc-3PRGD2 in non-human primates[J]. Mol Imaging Biol, 2011, 13(4): 730−736. DOI: 10.1007/s11307-010-0385-y. [7] Dong F, Li L, Bian YZ, et al. Standardized uptake value using thyroid quantitative SPECT/CT for the diagnosis and evaluation of graves' disease: a prospective multicenter study[J/OL]. Biomed Res Int, 2019, 2019: 7589853[2023-01-03]. https://www.hindawi.com/journals/bmri/2019/7589853/. DOI: 10.1155/2019/7589853. [8] Fu H, Wu J, Huang JX, et al. 68Ga fibroblast activation protein inhibitor PET/CT in the detection of metastatic thyroid cancer: comparison with 18F-FDG PET/CT[J]. Radiology, 2022, 304(2): 397−405. DOI: 10.1148/radiol.212430. [9] Xu QF, Liu RC, Wang J, et al. Role of [99mTc]Tc-galacto-RGD2 SPECT/CT in identifying metastatic differentiated thyroid carcinoma after thyroidectomy and radioactive iodine therapy[J]. Nucl Med Biol, 2020, 88-89: 34−43. DOI: 10.1016/j.nucmedbio.2020.06.006. [10] Zhang Y, Lin ZY, Li T, et al. Head-to-head comparison of 99mTc-PSMA and 99mTc-MDP SPECT/CT in diagnosing prostate cancer bone metastasis: a prospective, comparative imaging trial[J/OL]. Sci Rep, 2022, 12(1): 15993[2023-01-03]. https://www.nature.com/articles/s41598-022-20280-x. DOI: 10.1038/s41598-022-20280-x. [11] Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy[J]. J Clin Endocrinol Metab, 2006, 91(8): 2892−2899. DOI: 10.1210/jc.2005-2838. [12] Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer[J]. N Engl J Med, 2015, 372(7): 621−630. DOI: 10.1056/NEJMoa1406470. [13] Fu H, Fu J, Huang JX, et al. 68Ga-FAPI PET/CT versus 18F-FDG PET/CT for detecting metastatic lesions in a case of radioiodine-refractory differentiated thyroid cancer[J]. Clin Nucl Med, 2021, 46(11): 940−942. DOI: 10.1097/RLU.0000000000003730. [14] Liu J, Yuan SH, Wang LL, et al. Diagnostic and predictive value of using RGD PET/CT in patients with cancer: a systematic review and meta-analysis[J/OL]. Biomed Res Int, 2019, 2019: 8534761[2023-01-03]. https://www.hindawi.com/journals/bmri/2019/8534761/. DOI: 10.1155/2019/8534761. [15] Zhang Y, Li YX, Lin ZY, et al. Can 99Tcm-3PRGD2(ανβ3) and 18F-FDG dual-tracer molecular imaging change the therapeutic strategy for progressive refractory differentiated thyroid cancer: case report[J]. Medicine (Baltimore), 2023, 102(5): e32751. DOI: 10.1097/MD.0000000000032751. [16] Schlumberger M, Brose M, Elisei R, et al. Definition and management of radioactive iodine-refractory differentiated thyroid cancer[J]. Lancet Diabetes Endocrinol, 2014, 2(5): 356−358. DOI: 10.1016/S2213-8587(13)70215-8. [17] Kang SY, Bang JI, Kang KW, et al. FDG PET/CT for the early prediction of RAI therapy response in patients with metastatic differentiated thyroid carcinoma[J/OL]. PLoS One, 2019, 14(6): e0218416[2023-01-03]. https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0218416. DOI: 10.1371/journal.pone.0218416. [18] Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial[J]. Lancet, 2014, 384(9940): 319−328. DOI: 10.1016/S0140-6736(14)60421-9. [19] Lee EK, Kim SM, Kim BH, et al. Lesion-based evaluation predicts treatment response to lenvatinib for radioactive iodine-refractory differentiated thyroid cancer: a Korean multicenter retrospective study[J]. Thyroid, 2019, 29(12): 1811−1819. DOI: 10.1089/thy.2019.0022. [20] Lin YS, Qin SK, Li ZY, et al. Apatinib vs placebo in patients with locally advanced or metastatic, radioactive iodine-refractory differentiated thyroid cancer: the REALITY randomized clinical trial[J]. JAMA Oncol, 2022, 8(2): 242−250. DOI: 10.1001/jamaoncol.2021.6268. [21] Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease[J]. Nat Med, 1995, 1(1): 27−30. DOI: 10.1038/nm0195-27.